Catalyst
Slingshot members are tracking this event:
Insys Therapeutics Reports Phase 3 Trial of Sublingual Buprenorphine Spray Met Primary Endpoint in Patients with Moderate-to-Severe Postoperative Pain after Bunionectomy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| INSY |
|
|
||||
Additional Information
The primary efficacy endpoint was statistically significant at all doses studied. The Buprenorphine Sublingual Spray 0.5 mg tid demonstrated the largest reduction in SPID-48 and was statistically significant to placebo (p<0.0001). The 0.25 mg tid and 0.125 mg tid doses also demonstrated statistically significant reductions in SPID-48 (p = 0.0108 and p = 0.0120, respectively). All treatments were generally well tolerated.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 24, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Buprenorphine Spray, Primary Endpoint, Bunionectomy, Postoperative Pain
